Therefore, MASLD inferred from an FLI ≥ 60 confers higher plasma LCAT and, to a lesser extent, phospholipid transfer protein activity, even when accounting for T2DM, MetS, central obesity, and insulin resistance [47]. The gene discussed is LCAT; the disease is metabolic syndrome.